Liberia

NBC NEWS   by Maggie Fox                              June 17, 2015         

Does Ebola stay in your eyes after you recover? Can it spread via semen? Why does it cause achey joints?

U.S. researchers are launching a study in Liberia to take a look at survivors of the deadly virus to see just how common these long-term effects are, and whether they contribute to outbreaks.

"To unravel the many unknowns, we have expanded the focus of our partnership with Liberia's Ministry of Health to include research on the long-term health effects of Ebola virus disease, in addition to our ongoing efforts to find an effective preventive vaccine and treatments for Ebola virus disease," said Dr. Tony Fauci, director of the National Institute of Allergy and Infectious Disease.

Liberia's health ministry and the NIAID will be studying 1,500 Ebola survivors and 6,000 of their close contacts. They'll look at sweat, tears, semen and other bodily fluids in the survivors and follow everyone for as long as five years.

REUTERS by Kate Keller and Ben Hirschler                                      June 17, 2015

LONDON --Drugmakers' plans to conduct vast clinical trials to test and hopefully validate the first Ebola vaccines have been thwarted by success in beating back the deadly epidemic in West Africa.

GlaxoSmithKline, Merck and Johnson & Johnson are struggling to recruit volunteers with enough exposure to the disease to prove whether their vaccines are doing the job and preventing infection.

The story might have been very different with just another three or four months of disease spread, underscoring the need to act more quickly to develop vaccines for emerging diseases....

Guinea, where Ebola is still infecting new victims, as "the only hope" for showing efficacy, according to Kieny and to Adrian Hill, director of the Jenner Institute at Britain's Oxford University.

The WHO is overseeing the so-called ring vaccination study in Guinea in which close contacts and family around each new case of Ebola are vaccinated -- either immediately or after a three-week delay -- to see if the shot offers protection.

Read complete story.

The latest Ebola crisis may yield clues about where it hides between outbreaks.

GLOBAL LITERACY PROJECT                                       June  15, 2015
abstract of article in
NATIONAL GEOGRAPHIC  by  David Quammen   
(Scroll down for full article.)       

   Picture of a masked bush meat hunter. Peter Muller.

PUBLIC BROADCASTING CORP by Caleb Hellerman         June 11, 2015

The quest for an Ebola vaccine has been a journey filled with excruciating delays and mad dashes. The latest outbreak in West Africa caused governments and drug companies to jumpstart research that had languished back when the threat of Ebola wasn’t big enough to sustain a commercial market. (Prior to 2013, the virus had sickened fewer than 2,300 people in known history). Human safety trials of two vaccines began last summer — each being given to a small group of healthy volunteers. When no major side effects were apparent, health officials scrambled to launch larger tests in the countries that were most affected by Ebola.

A volunteer receives an Ebola vaccine in Sierra Leone. Thousands of these voluntary immunizations have been tested so far in the West African nation. Photo by Cameron Hickey.